They observed 6 patients had a PR, 14 had SD, and 5 had PD through the course of treatment (the 2-year PFS rate was 78 ± 8.5%). Again, the most common toxicities were grade 1/2, but notable grade 3 AEs included creatine kinase elevation (5%) with 3% of cases being grade 4,...
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained remissions in these patients. However, CAR T cells can result in significant toxicities. Preinfusion disease burden ...
According to the biological process category of gene ontology analysis, retina homeostasis may play a critical role in low-grade serous ovarian cancer. A breakthrough in Kessler’s study, understanding of the molecular biology of ovarian cancer may depend on gaining a deeper insight into retina hom...
Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis. ...
And easy to relapse, is the lowest long-term survival rate of subtype lymphoma. The clinical manifestations are usually high fever and fatigue, splenic and lymph node enlargement, gastrointestinal involvement and nervous system invasion. At present, the first-line treatment for CLL is FCR, that ...